Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amylin Pharmaceuticals Inc.
July 02 2012 - 11:40AM
Business Wire
Pomerantz Haudek Grossman & Gross LLP is investigating
claims on behalf of investors of Amylin Pharmaceuticals Inc.
(“Amylin” or the “Company”) (NASDAQ: AMLN) (ISIN: US0323461089)
concerning the proposed acquisition of Amylin by Bristol-Myers
Squibb Co. in a cash transaction valued at approximately $5.3
billion.
The investigation concerns whether the Amylin directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms of the
agreement, Amylin shareholders would receive $31.00 in cash per
share of Amylin common stock. However, it is unclear whether the
price offered by Bristol-Myers adequately compensates Amylin
shareholders.
Amylin shareholders seeking more information about this
acquisition are advised to contact Rebecca Jarmon at
rjarmon@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 314.
The Pomerantz Firm, with offices in New York and Chicago, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the dean of the class action bar,
the Pomerantz Firm pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of defrauded
investors. See www.pomerantzlaw.com.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Oct 2023 to Oct 2024